Sarepta Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Sarepta Therapeutics (SRPT) PT Lowered to $190 at RBC Capital
October 25, 2018 7:30 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $190.00 (from $200.00) while maintaining a Outperform rating.
The analyst commented, "With Exondys 51 meeting expectations and the company continuing to execute on multiple clinical gene therapy and RNA development... More
Sarepta Therapeutics (SRPT) Posts Smaller-than-Expected Q3 Loss
October 24, 2018 4:10 PM EDTSarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($0.56), $0.25 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $78.5 million versus the consensus estimate of $79.26 million.
We are pleased to report another positive quarter, delivering strong EXONDYS 51 sales and tracking to... More
